Pancreatic Cancer Research

ResearcherTokyo Medical UniversityNo recent work listed

Masato Matsuyama

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3604-1624; OpenAlex author ID A5000489992. Sources: OpenAlex.

Their work

Papers
32 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 4 papers · 2021: 9 papers · 2022: 6 papers · 2023: 6 papers

Papers 32

  1. The efficacy and safety of a duckbill-type anti-reflux metal stent as the initial metal stent for distal malignant biliary obstruction in unresectable pancreat… Co-author DOI 10.1002/deo2.205↗
  2. Outcomes of pancreatic cancer with liver oligometastasis. Co-author DOI 10.1002/jhbp.1184↗
  3. Long-term outcomes of duckbill-type anti-reflux metal stents versus conventional covered metal stents in reinterventions after covered biliary metal stent dysf… Co-author DOI 10.1007/s00464-022-09836-0↗
  4. Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel. Co-author DOI 10.1016/j.pan.2023.02.002↗
  5. Impact of the Extent of Weight Loss before Administration on the Efficacy of Anamorelin in Advanced Pancreatic Cancer Patients with Cachexia. Co-author DOI 10.2169/internalmedicine.0730-22↗
  6. Treatment Outcomes and Prognostic Factors of Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy after Modified FOLFIRINOX in Unresectable Pancreatic C… Co-author DOI 10.3390/cancers15020358↗
  7. Early-onset pancreatic cancer: Clinical characteristics and survival outcomes. Co-author DOI 10.1016/j.pan.2022.04.003↗
  8. Treatment outcomes of nanoliposomal irinotecan as second-line chemotherapy after gemcitabine and nab-paclitaxel in metastatic and recurrent pancreatic cancer. Co-author DOI 10.1093/jjco/hyac145↗
  9. Impact of the COVID-19 Pandemic on the Management and End-of-life Care of Unresectable Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.0492-22↗
  10. Multiple Gastric Metastases after Distal Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.2169/internalmedicine.8848-21↗
  11. CA19-9 Reduction After 4 Months of Treatment Is a Prognostic Factor for Locally Advanced Pancreatic Cancer. Co-author DOI 10.21873/invivo.13024↗
  12. Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. Co-author DOI 10.3390/ijms23031205↗
  13. Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. Co-author DOI 10.1007/s10147-020-01827-2↗
  14. The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. Co-author DOI 10.1007/s10147-021-01912-0↗
  15. A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s12328-021-01480-w↗
  16. Improved prognosis of pancreatic cancer patients with peritoneal metastasis. Co-author DOI 10.1016/j.pan.2021.03.006↗
  17. The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyaa247↗
  18. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyab014↗
  19. Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyab091↗
  20. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancre… Co-author DOI 10.1097/mpa.0000000000001801↗
  21. CT Abnormalities of the Pancreas Associated With the Subsequent Diagnosis of Clinical Stage I Pancreatic Ductal Adenocarcinoma More Than 1 Year Later: A Case-C… Co-author DOI 10.2214/ajr.21.26014↗
  22. Comprehensive comparison of clinicopathological characteristics, treatment, and prognosis of borderline resectable pancreatic cancer according to tumor locatio… Co-author DOI 10.1016/j.pan.2020.07.004↗
  23. Genome-wide association meta-analysis identifies GP2 gene risk variants for pancreatic cancer. Co-author DOI 10.1038/s41467-020-16711-w↗
  24. Novel risk factors for recurrent biliary obstruction and pancreatitis after metallic stent placement in pancreatic cancer. Co-author DOI 10.1055/a-1244-1989↗
  25. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. Co-author DOI 10.1186/s12885-020-06945-8↗
  26. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis. Co-author DOI 10.21873/invivo.11471↗
  27. Associations between polymorphisms in folate-metabolizing genes and pancreatic cancer risk in Japanese subjects. Co-author DOI 10.1186/s12876-016-0503-7↗
  28. Genome-wide association study-identified SNPs (rs3790844, rs3790843) in the NR5A2 gene and risk of pancreatic cancer in Japanese. Co-author DOI 10.1038/srep17018↗
  29. Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a sin… Co-author DOI 10.1093/jjco/hyu159↗
  30. Lack of associations between genetic polymorphisms in GSTM1, GSTT1 and GSTP1 and pancreatic cancer risk: a multi-institutional case-control study in Japan. First author DOI 10.7314/apjcp.2014.15.1.391↗
  31. [FOLFIRINOX-induced hyperammonemic encephalopathy in a patient with pancreatic cancer]. Co-author PMID 25373377↗
  32. Ultrasound-guided vs endoscopic ultrasound-guided fine-needle aspiration for pancreatic cancer diagnosis. Co-author DOI 10.3748/wjg.v19.i15.2368↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Masato Ozaka · 27 shared papers, 2014–2023 · strength 3.43
  2. Takashi Sasaki · 25 shared papers, 2019–2023 · strength 3.42
  3. Naoki Sasahira · 25 shared papers, 2019–2023 · strength 3.42
  4. Tsuyoshi Takeda · 23 shared papers, 2020–2023 · strength 3.18
  5. Akiyoshi Kasuga · 23 shared papers, 2020–2023 · strength 3.18
  6. Takafumi Mie · 22 shared papers, 2020–2023 · strength 3.00
  7. Takaaki Furukawa · 22 shared papers, 2020–2023 · strength 3.00
  8. Yuto Yamada · 16 shared papers, 2020–2023 · strength 2.14
  9. Takeshi Okamoto · 14 shared papers, 2021–2023 · strength 2.08
  10. Yu Takahashi · 5 shared papers, 2020–2023 · strength 0.66
  11. Hiroki Nakagawa · 4 shared papers, 2022–2023 · strength 0.62
  12. Yosuke Inoue · 3 shared papers, 2020–2023 · strength 0.41
  13. Akio Saiura · 3 shared papers, 2015–2023 · strength 0.34
  14. Dai Inoue · 4 shared papers, 2014–2021 · strength 0.26
  15. Manabu Takamatsu · 2 shared papers, 2021–2022 · strength 0.25
  16. Ikuhiro YAMADA · 4 shared papers, 2014–2019 · strength 0.25
  17. Hiroshi Ishii · 5 shared papers, 2014–2016 · strength 0.21
  18. Tsuyoshi Hamada · 1 shared paper, 2023 · strength 0.16
  19. Akio Saiura · 1 shared paper, 2022 · strength 0.13
  20. Yuta Ushida · 1 shared paper, 2022 · strength 0.13
  21. Fumihito Toshima · 1 shared paper, 2021 · strength 0.12
  22. Toshifumi Gabata · 1 shared paper, 2021 · strength 0.12
  23. Yoshihiro Ono · 1 shared paper, 2021 · strength 0.11
  24. Shinichi Ohkawa · 3 shared papers, 2014–2016 · strength 0.11
  25. Kozue Nakamura · 3 shared papers, 2014–2016 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.